<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/53628564-08D1-40A6-B643-73D04DA72665"><gtr:id>53628564-08D1-40A6-B643-73D04DA72665</gtr:id><gtr:name>Blueberry Therapeutics Limited</gtr:name><gtr:address><gtr:line1>5 Sutton Road
Alderley Edge</gtr:line1><gtr:city>Cheshire</gtr:city><gtr:postCode>SK9 7RB</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53628564-08D1-40A6-B643-73D04DA72665" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>53628564-08D1-40A6-B643-73D04DA72665</gtr:id><gtr:name>Blueberry Therapeutics Limited</gtr:name><gtr:address><gtr:line1>5 Sutton Road
Alderley Edge</gtr:line1><gtr:city>Cheshire</gtr:city><gtr:postCode>SK9 7RB</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>24419.0</gtr:offerGrant><gtr:projectCost>40699.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0F23344E-1EF1-4024-9EE7-76D441818EA4"><gtr:id>0F23344E-1EF1-4024-9EE7-76D441818EA4</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700571"><gtr:id>0999B901-9FFC-48F5-BFB0-143CDD875E5F</gtr:id><gtr:title>Nanoparticle Formulation for the Treatment of Tinea Pedis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700571</gtr:grantReference><gtr:abstractText>Tinea pedis, also known as athlete?s foot, is a common dermatophytic infection, which is
extremely difficult to eradicate. Its symptoms include pruritic, scaly soles and often painful
fissures between the toes. Tinea pedis is currently treated with topical or oral antifungals,
which are usually used for 1-6 weeks. However recurrences are common with up to 90% of
cases. Blueberry Therapeutics have noted this lack of curative treatment and have devised a
nanoparticle formulation, which will be ideal for spray delivery direct to the feet and
interdigital spaces as well as a biocide to treat clothes and footwear.</gtr:abstractText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>24419</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700571</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>